The mRNA vaccine is taken up by APCs, which present neoantigens on MHC I/II to prime T cells; vaccine-induced T cells then kill neoantigen-expressing tumor cells—primarily via CD8+ CTL perforin/granzyme or Fas–FasL, with CD4+ T cells providing help and potentially killing MHC II–positive tumor cells.